The findings indicated that the pairing of naringin and cisplatin effectively decreased the dimensions of transplanted tumors, the levels of tumor markers CA125 and HE4, along with the heterogeneity of cancerous cells and the proportion of Ki67-positive cells in tissue samples. The gene discussed is WFDC2; the disease is neoplasm.